Skip to main content
Clinical Trials/NCT04783402
NCT04783402
Enrolling By Invitation
Not Applicable

A Telehealth-based Cognitive-adaptive Training for Women With Breast Cancer in Risk to Suffer Cancer and Chemotherapy-related Cognitive Impairment: a Randomized Controlled Trial.

Universidad de Granada1 site in 1 country98 target enrollmentOctober 31, 2020

Overview

Phase
Not Applicable
Intervention
Not specified
Conditions
Breast Neoplasms
Sponsor
Universidad de Granada
Enrollment
98
Locations
1
Primary Endpoint
Subjective cognitive Function:
Status
Enrolling By Invitation
Last Updated
2 years ago

Overview

Brief Summary

The present randomized controlled trial has the main objective to study the effects of a videoconferenced occupational therapy program in preventing cancer and chemotherapy-related cognitive impairment and other health outcomes, as well as in improving quality of live and occupational performance of women undergoing chemotherapy for breast cancer.

Detailed Description

The chemotherapy-related cognitive impairment (also called chemobrain) has a great incidence among breast cancer population. However, the knowledge about effective interventions of supportive care is still inconsistent. Furthermore, the majority of programs targeted to this problem has been applied in survivorship, while the onset of cognitive impairment and the decline in quality of life occur during medical treatments. In this line, actual evidence suggests testing the effectiveness of interventions in a preventive setting in patients with breast cancer scheduled to receive neurotoxic chemotherapy. In addition, telehealth approaches have become a promising practice and increasingly more frequent among healthcare disciplines. Our objective is to study the effects of a videoconferenced cognitive training in combination with cognitive-behavioral strategies to prevent or mitigate the cancer- and chemotherapy-related cognitive impairment in women with breast cancer who undergo this treatment, as well as to improve quality of life and allow an optimal adaptation to the occupational needs derived from medical treatment. This study will use a two-arm, single blinded randomized clinical trial design. Eligible women will be randomized to one of the following groups: the experimental group that will receive the e-OTCAT program (12 weeks), or the control group that will receive and educational handbook and standard care. The study outcomes will be assessed after intervention and at 6-month follow-up post-randomization. This study may contribute the need to include disciplines such as occupational therapy in the supportive care of cancer patients during the active phase of the disease, as well as the potential advantages provided by a telehealth approach related to economic, temporal and geographical barriers.

Registry
clinicaltrials.gov
Start Date
October 31, 2020
End Date
December 30, 2024
Last Updated
2 years ago
Study Type
Interventional
Study Design
Parallel
Sex
Female

Investigators

Responsible Party
Principal Investigator
Principal Investigator

Lydia Mª Martín-Martín

Lecturer, PhD researcher and investigator

Universidad de Granada

Eligibility Criteria

Inclusion Criteria

  • Female with breast cancer who are going to start chemotherapy
  • Stage I-III breast cancer
  • No evidence of disease at time of screening
  • Must be able to speak, read and write Spanish well to complete written and verbal assessment, neurocognitive tests and study tasks
  • Must have basic phone skills

Exclusion Criteria

  • History of neurological disorder with cognitive symptoms (i.e., Parkinson's disease, Alzheimer disease, seizure disorder, multiple sclerosis, etc.)
  • History of psychiatric disorder such as mental retardation, bipolar disorder, schizophrenia, etc.
  • History of traumatic brain injury with ≥ 30' of consciousness or cognitive sequelae as per self-report or as documented in the medical record
  • Prior history of cancer or secondary diagnosis of cancer
  • Prior history of chemotherapy
  • A hearing or visual deficit

Outcomes

Primary Outcomes

Subjective cognitive Function:

Time Frame: Participants will be followed over 6 months

The primary outcome will be assessed with the Functional Assessment of Cancer Therapy-Cognitive Function (FACT-Cog) will be used to assess the subjective cognitive functioning.

Secondary Outcomes

  • Overall Quality of Life(Participants will be followed over 6 months)
  • Objective Cognitive Function: Attention(Participants will be followed over 6 months)
  • Objective Cognitive Function: Working Memory and Processing Speed(Participants will be followed over 6 months)
  • Psychological status(Participants will be followed over 6 months)
  • Cancer-Related Fatigue(Participants will be followed over 6 months.)
  • Objective Cognitive Function: Verbal Memory(Participants will be followed over 6 months)
  • Quality of Sleep(Participants will be followed over 6 months.)
  • Occupational Performance(Participants will be followed over 6 months)

Study Sites (1)

Loading locations...

Similar Trials